These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9479598)

  • 1. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
    Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
    Int J Biol Markers; 1997; 12(3):134-6. PubMed ID: 9479598
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
    Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
    Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6 is a survival prognostic factor in renal cell carcinoma.
    Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
    Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
    Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
    Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
    Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
    Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer.
    Lissoni P; Rovelli F; Vellani D; Malugani F; Bucovec R; Chapovalenko L; Fumagalli E; Gardani G
    Int J Biol Markers; 2001; 16(2):146-7. PubMed ID: 11471899
    [No Abstract]   [Full Text] [Related]  

  • 8. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
    Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
    J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
    Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
    Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
    Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
    Bonfanti A; Lissoni P; Bucovec R; Rovelli F; Brivio F; Fumagalli L
    Int J Biol Markers; 2000; 15(2):161-4. PubMed ID: 10883890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P; Mandalà M; Brivio F
    Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
    Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
    Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Ramsey S; Aitchison M
    J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble immunological parameters and early prognosis of renal cell cancer patients.
    Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
    J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
    Vannier E; Kaser A; Atkins MB; Fantuzzi G; Dinarello CA; Mier JW; Tilg H
    Eur Cytokine Netw; 1999 Mar; 10(1):37-42. PubMed ID: 10210771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy.
    Kedar I; Mermershtain W; Ivgi H
    Int J Cancer; 2004 Jun; 110(2):260-5. PubMed ID: 15069691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.